BioSpace News Archive

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of best-in-class bioproduction tools for cell and gene therapies, today announced a co-investment accelerator program with Casdin Capital, targeting early stage companies that are developing novel cell and gene therapy bioproduction tools.

Alliance Contract Pharma (ACP) announced today that the Company’s new $2 million Liquid Capsule filling line is fully operational.

Healthcare Transformation Specialist to Focus on Due Diligence, Deal Execution and Portfolio Support

Benvenue Medical, Inc., an innovative developer of minimally invasive surgery (MIS) expandable implant solutions for lumbar fusions, today announced data demonstrating clinical results of improved relief of back pain and leg pain, as well as lowered Oswestry Disability Index (ODI) scores at 12 months post-op with its Luna™ product.

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, today announced that John P. Butler, President and Chief Executive Officer of Akebia, will present at the 2019 Cantor Global Healthcare Conference at 8:55 a.m. ET on Thursday, October 3, 2019 in New York City.

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has dosed the first patients in its Phase 3 clinical trial of DEXTENZA® for the treatment of symptoms of allergic conjunctivitis (AC).

Eisai today announced the presentation of new data and analyses via one oral proffered paper presentation, four poster discussions and seven poster presentations at the 2019 European Society for Medical Oncology (ESMO) Annual Meeting from September 27 – October 1 in Barcelona, Spain.

29th International Congress of the European Respiratory Society (ERS) being held September 28th - October 2nd in Madrid, Spain.

Remains Comfortable with Level of Reserves as of September 23, 2019

$101,424,000, compared to the previous year’s first quarter revenues of $99,626,000.